CA2301599C - 4-oxo-naphtyridine-3-carboxamides substitues comme ligands de recepteur de gaba du cerveau - Google Patents
4-oxo-naphtyridine-3-carboxamides substitues comme ligands de recepteur de gaba du cerveau Download PDFInfo
- Publication number
- CA2301599C CA2301599C CA002301599A CA2301599A CA2301599C CA 2301599 C CA2301599 C CA 2301599C CA 002301599 A CA002301599 A CA 002301599A CA 2301599 A CA2301599 A CA 2301599A CA 2301599 C CA2301599 C CA 2301599C
- Authority
- CA
- Canada
- Prior art keywords
- dihydro
- oxo
- naphthyridine
- carboxamide
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des structures de la formule (I) ou leurs sels non toxiques et acceptables du point de vue pharmaceutique; dans la formule (I): X est hydrogène, halogène, alkyle (non) substitué, alcoxy ou amine (non) substitué; et Y est alkyle (non) substitué, aryle ou hétéroaryle; ces composés sont des agonistes, antagonistes ou agonistes inverses de récepteurs de GABAa du cerveau ou des promédicaments d'agonistes, d'antagonistes ou d'agonistes inverses de récepteurs de GABAa du cerveau. Ces composés s'utilisent dans le diagnostic et le traitement de l'anxiété, du syndrome de Down, du sommeil, de troubles cognitifs et épileptiques et de l'overdose de médicaments au benzodiazépine et pour l'activation de la vigilance.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91818097A | 1997-08-25 | 1997-08-25 | |
US08/918,180 | 1997-08-25 | ||
PCT/US1998/017513 WO1999010347A1 (fr) | 1997-08-25 | 1998-08-24 | 4-oxo-naphtyridine-3-carboxamides substitues comme ligands de recepteur de gaba du cerveau |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2301599A1 CA2301599A1 (fr) | 1999-03-04 |
CA2301599C true CA2301599C (fr) | 2003-03-25 |
Family
ID=25439933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002301599A Expired - Fee Related CA2301599C (fr) | 1997-08-25 | 1998-08-24 | 4-oxo-naphtyridine-3-carboxamides substitues comme ligands de recepteur de gaba du cerveau |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1007526A1 (fr) |
JP (1) | JP2001514181A (fr) |
KR (1) | KR20010023313A (fr) |
CN (1) | CN1268136A (fr) |
AP (1) | AP2000001742A0 (fr) |
AU (1) | AU753800B2 (fr) |
BG (1) | BG104192A (fr) |
BR (1) | BR9811362A (fr) |
CA (1) | CA2301599C (fr) |
EG (1) | EG21717A (fr) |
HU (1) | HUP0003258A3 (fr) |
IL (1) | IL134291A0 (fr) |
IS (1) | IS5382A (fr) |
LV (1) | LV12539B (fr) |
NO (1) | NO20000822L (fr) |
NZ (1) | NZ502548A (fr) |
OA (1) | OA11293A (fr) |
PE (1) | PE130999A1 (fr) |
PL (1) | PL338783A1 (fr) |
SI (1) | SI20270A (fr) |
SK (1) | SK2162000A3 (fr) |
TW (1) | TW574221B (fr) |
WO (1) | WO1999010347A1 (fr) |
YU (1) | YU10500A (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4818000A (en) * | 1999-05-06 | 2000-11-21 | Neurogen Corporation | Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands |
WO2000071528A1 (fr) * | 1999-05-25 | 2000-11-30 | Neurogen Corporation | 4h-1,4-benzothiazine-2-carboxamides et leur utilisation en tant que ligands des recepteurs cerebraux gaba |
US6730682B2 (en) | 2000-07-12 | 2004-05-04 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
US6559145B2 (en) | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
US6562822B2 (en) | 2000-07-12 | 2003-05-13 | Pharmacia & Upjohn Company | Heterocyle carboxamides as antiviral agents |
ES2287170T3 (es) | 2000-10-12 | 2007-12-16 | MERCK & CO., INC. | Aza- y poliaza-naftalenil-carboxamidas utilies como inhibidores de la vih integrasa. |
CA2425625A1 (fr) | 2000-10-12 | 2002-07-18 | Merck & Co., Inc. | Aza- et polyaza-naphthalenyl carboxamides convenant comme inhibiteurs de l'integrase du vih |
WO2002030930A2 (fr) | 2000-10-12 | 2002-04-18 | Merck & Co., Inc. | Aza- et polyaza-naphthalenyl carboxamides utiles comme inhibiteurs de l'integrase du vih |
US20020151591A1 (en) * | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
SK10752003A3 (sk) * | 2001-03-01 | 2004-08-03 | Pfizer Products Inc. | Použitie inverzných agonistov GABAA v kombinácii s parciálnymi agonistami receptora nikotínu, estrogénom, selektívnymi modulátormi estrogénu alebo vitamínom E pri liečení kognitívnych porúch |
AR036256A1 (es) | 2001-08-17 | 2004-08-25 | Merck & Co Inc | Sal sodica de un inhibidor de integrasa del vih, procesos para su preparacion, composiciones farmaceuticas que lo contienen y su uso para la manufactura de un medicamento |
ATE370948T1 (de) | 2002-01-17 | 2007-09-15 | Merck & Co Inc | Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen |
WO2003077850A2 (fr) | 2002-03-15 | 2003-09-25 | Merck & Co., Inc. | N-(benzyl substitue)-8-hydroxy-1,6-naphthyridine-7- carboxamides utiles en tant qu'inhibiteurs d'integrase de hiv |
WO2004106336A1 (fr) * | 2003-05-27 | 2004-12-09 | Pfizer Products Inc. | Procede de preparation et de purification de 1,5-naphtyridine-3-carboxyamides |
WO2004106334A2 (fr) * | 2003-05-28 | 2004-12-09 | Pfizer Products Inc. | Procede de preparation de 1,5-naphtyridine-3-carboxyamides par amidation directe d'esters |
PL2074123T3 (pl) * | 2006-10-16 | 2013-04-30 | Bionomics Ltd | Nowe związki o działaniu przeciwlękowym |
ES2610508T3 (es) * | 2006-11-22 | 2017-04-27 | Clinical Research Associates, Llc | Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR204813A1 (es) * | 1972-05-08 | 1976-03-05 | Yamanouchi Pharma Co Ltd | Proceso para la preparacion de derivados de ampilicina |
GB1433774A (en) * | 1973-02-26 | 1976-04-28 | Allen & Hanburys Ltd | Heterocyclic compounds apparatus for conveying articles |
US4374138A (en) * | 1981-11-13 | 1983-02-15 | Warner-Lambert Company | Antibacterial amide compounds, compositions, and methods of use |
DD295360A5 (de) * | 1987-07-03 | 1991-10-31 | Akad Wissenschaften | Verfahren zur Herstellung von aktivierten Carbonsäureestern |
DD279887A1 (de) * | 1987-07-03 | 1990-06-20 | Inst Pharmakologische Forschun | Verfahren zur herstellung von d-alpha-(4(1h)-1,5-naphthyridon-3-carboxamido)-benzylpenicillin und anderen beta-lactamantibiotika |
DD279875A1 (de) * | 1987-07-03 | 1990-06-20 | Inst Pharmakologische Forschun | Verfahren zur herstellung von aktivierten carbonsaeureestern |
JPS6461461A (en) * | 1987-09-01 | 1989-03-08 | Otsuka Pharma Co Ltd | Benzohetero ring derivative |
-
1998
- 1998-08-24 WO PCT/US1998/017513 patent/WO1999010347A1/fr not_active Application Discontinuation
- 1998-08-24 SI SI9820055A patent/SI20270A/sl unknown
- 1998-08-24 CA CA002301599A patent/CA2301599C/fr not_active Expired - Fee Related
- 1998-08-24 HU HU0003258A patent/HUP0003258A3/hu unknown
- 1998-08-24 EP EP98943352A patent/EP1007526A1/fr not_active Withdrawn
- 1998-08-24 PL PL98338783A patent/PL338783A1/xx unknown
- 1998-08-24 YU YU10500A patent/YU10500A/sh unknown
- 1998-08-24 CN CN98808578A patent/CN1268136A/zh active Pending
- 1998-08-24 AU AU91173/98A patent/AU753800B2/en not_active Ceased
- 1998-08-24 KR KR1020007001948A patent/KR20010023313A/ko not_active Application Discontinuation
- 1998-08-24 SK SK216-2000A patent/SK2162000A3/sk unknown
- 1998-08-24 BR BR9811362-3A patent/BR9811362A/pt not_active Application Discontinuation
- 1998-08-24 JP JP2000507675A patent/JP2001514181A/ja active Pending
- 1998-08-24 IL IL13429198A patent/IL134291A0/xx unknown
- 1998-08-24 NZ NZ502548A patent/NZ502548A/en unknown
- 1998-09-29 EG EG118098A patent/EG21717A/xx active
- 1998-10-23 TW TW87117597A patent/TW574221B/zh active
- 1998-11-13 PE PE1998001100A patent/PE130999A1/es not_active Application Discontinuation
-
2000
- 2000-02-01 AP APAP/P/2000/001742A patent/AP2000001742A0/en unknown
- 2000-02-18 OA OA1200000044A patent/OA11293A/en unknown
- 2000-02-18 NO NO20000822A patent/NO20000822L/no not_active Application Discontinuation
- 2000-02-22 IS IS5382A patent/IS5382A/is unknown
- 2000-02-25 BG BG104192A patent/BG104192A/xx unknown
- 2000-03-16 LV LVP-00-29A patent/LV12539B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU753800B2 (en) | 2002-10-31 |
BG104192A (en) | 2001-05-31 |
NO20000822L (no) | 2000-04-13 |
TW574221B (en) | 2004-02-01 |
SI20270A (sl) | 2000-12-31 |
PL338783A1 (en) | 2000-11-20 |
LV12539B (en) | 2001-01-20 |
CA2301599A1 (fr) | 1999-03-04 |
JP2001514181A (ja) | 2001-09-11 |
PE130999A1 (es) | 1999-12-16 |
BR9811362A (pt) | 2000-08-22 |
NZ502548A (en) | 2002-06-28 |
LV12539A (en) | 2000-10-20 |
NO20000822D0 (no) | 2000-02-18 |
IS5382A (is) | 2000-02-22 |
OA11293A (en) | 2002-11-19 |
HUP0003258A2 (en) | 2001-03-28 |
YU10500A (sh) | 2002-10-18 |
AP2000001742A0 (en) | 2000-02-24 |
SK2162000A3 (en) | 2001-03-12 |
IL134291A0 (en) | 2001-04-30 |
WO1999010347A1 (fr) | 1999-03-04 |
KR20010023313A (ko) | 2001-03-26 |
EP1007526A1 (fr) | 2000-06-14 |
EG21717A (en) | 2002-02-27 |
HUP0003258A3 (en) | 2001-05-28 |
AU9117398A (en) | 1999-03-16 |
CN1268136A (zh) | 2000-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6399604B1 (en) | Substituted 4-OXO-napthyridine-3-carboxamides; GABA brain receptor ligands | |
CA2301599C (fr) | 4-oxo-naphtyridine-3-carboxamides substitues comme ligands de recepteur de gaba du cerveau | |
US6103903A (en) | 4-(4-piperidylmethyhlamino) substituted heteroaryl fused pyridines: GABA brain receptor ligands | |
US6423711B1 (en) | Heterocyclic amino substituted heteroaryl fused pyridines; GABA brain receptor ligands | |
US6156898A (en) | Substituted 1,4-dihydro-4-oxonicotinic carboxamides; GABA brain receptor ligands | |
JP5524071B2 (ja) | 複素環フェニルアミドt型カルシウムチャネルアンタゴニスト | |
US6177569B1 (en) | Oxo-pyridoimidazole-carboxamides: GABA brain receptor ligands | |
US6414147B1 (en) | 2-amino-9-alkylpurines: GABA brain receptor ligands | |
JP2003533524A (ja) | ホスホジエステラーゼ阻害剤として有効な置換ピロロピリジノン誘導体 | |
WO1994005665A1 (fr) | Imidazopyrazinols a fusion aryle et cycloalkyle; nouvelle classe de ligands de recepteurs encephaliques gaba | |
US6194427B1 (en) | Substituted cycloalkyl-4-Oxonicotinic carboxamides; gaba brain receptor ligands | |
EP1086103B1 (fr) | Derives de pyrido 2, 3-b]indolizine et analogues aza associes; ligands crf 1 specifiques | |
EP1107966B1 (fr) | Oxo-pyridoimidazole-carboxamides: ligands du recepteur cerebral gaba | |
MXPA00001598A (en) | Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands | |
MXPA00008364A (en) | Substituted cycloalkyl-4-oxonicotinic carboxamides;gaba brain receptor ligands | |
MXPA01001991A (en) | Oxo-pyridoimidazole-carboxamides:gaba brain receptor ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |